Allergy Therapeutics (LSE:AGY) Research & Development: £16.56 Mil (TTM As of Dec. 2025)


What is Allergy Therapeutics Research & Development?

Allergy Therapeutics LSE:AGY Research & Development is £16.56 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Allergy Therapeutics's Research & Development for the six months ended in Dec. 2025 was £8.83 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was £16.56 Mil.

Allergy Therapeutics  (LSE:AGY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Allergy Therapeutics Research & Development Related Terms

Allergy Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Research & Development Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.89 15.66 20.12 22.90 15.38

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.39 11.51 7.65 7.73 8.83

Allergy Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £16.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of £16.56 Mil mean?
Allergy Therapeutics (LSE:AGY) has a Research & Development of £16.56 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' Research & Development too high?
Allergy Therapeutics' current Research & Development is £16.56 Mil.
How does Allergy Therapeutics' Research & Development compare to ZTS and UTHR?
Allergy Therapeutics' Research & Development of £16.56 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Allergy Therapeutics and its competitors. Allergy Therapeutics's current Research & Development is £16.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 133.3% above its estimated fair value. The current Research & Development is £16.56 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Research & Development is £16.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Allergy Therapeutics Business Description

Other Exchanges AGYTF:USAHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).